We also tested the effects of AdPROM-mediated SHP2 degradation on MAPK signalling in K-562 chronic myelogenous leukaemia cells, which naturally harbour the BCR-Abl fusion (figure 3d). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.